help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Davis, T. M.
Right arrow Articles by Bloom, S. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Davis, T. M.
Right arrow Articles by Bloom, S. R.

Journal of Clinical Endocrinology & Metabolism, Vol 65, 1248-1252, Copyright © 1987 by Endocrine Society

ARTICLES

Growth hormone (GH) release in response to GH-releasing hormone in man is 3-fold enhanced by galanin

TM Davis, JM Burrin and SR Bloom
Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London, United Kingdom.

The effect of GHRH in a dose (120 micrograms) thought to produce a maximal GH response was compared with the GH response to insulin- induced hypoglycemia, iv infusion of the hypothalamic neuropeptide galanin (40 pmol/kg.min for 40 min), and a combination of GHRH and galanin in normal men. The median peak serum GH level was 29 mU/L in response to GHRH, 28.9 mU/L in response to insulin hypoglycemia, 17.3 mU/L in response to galanin, and 115.0 mU/L in response to the combination of galanin and GHRH. GH release induced by galanin was completely inhibited by a concomitant somatostatin infusion (50 pmol/kg.min). Thus, galanin increased the peak GH response to GHRH, previously thought to be one of the most powerful stimulants to GH release, more than 3-fold. Since the dose of GHRH used was thought to be maximal and since galanin is reported not to have direct effects on the pituitary, one possible mode of action of galanin would be inhibition of tonic endogenous hypothalamic somatostatin release.


This article has been cited by other articles:


Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
J. F. Todd, C. M. B. Edwards, M. A. Ghatei, and S. R. Bloom
The differential effects of galanin-(1---30) and -(3---30) on anterior pituitary hormone secretion in vivo in humans
Am J Physiol Endocrinol Metab, June 1, 2000; 278(6): E1060 - E1066.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
N. YANAIHARA, T. MOCHIZUK, A. KUWAHARA, M. HOSHINO, H. KAKUYAMA, K. IGUCHI, T. IWANAGA, L. JUN, Y. FUTAI, T. KANNO, et al.
Endocrine and Gastrointestinal Action of Galanin
Ann. N.Y. Acad. Sci., December 21, 1998; 863(1): 129 - 142.
[Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
J. G. HOHMANN, D. K. CLIFTON, and R. A. STEINER
Galanin: Analysis of Its Coexpression in Gonadotropin-Releasing Hormone and Growth Hormone-Releasing Hormone Neurons
Ann. N.Y. Acad. Sci., December 21, 1998; 863(1): 221 - 235.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
A. Giustina and J. D. Veldhuis
Pathophysiology of the Neuroregulation of Growth Hormone Secretion in Experimental Animals and the Human
Endocr. Rev., December 1, 1998; 19(6): 717 - 797.
[Abstract] [Full Text]

Home page
 Endocr. Rev.Home page
D. Ray and S. Melmed
Pituitary Cytokine and Growth Factor Expression and Action
Endocr. Rev., April 1, 1997; 18(2): 206 - 228.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1987 by The Endocrine Society